ABSTRACT
Objective:To explore the clinical efficiency and safety of hemocoagulase used in dacryocystorhinostomy. Methods:Totally 116 cases (127 eyes) of patients with chronic dacryocystitis were randomly divided into the study group and the control group. The control group 55cases(60 eyes) only received dacryocystorhinostomy,while the study group 61cases(67 eyes) received 2 units of hemocoagulase intramuscularly before dacryocystorhinostomy. The intraoperative blood loss,nasal oozing rate of nasal cavity,coagula-tion function and patency of lacrimal passages after the operation were compared,and the adverse reactions were recorded as well. Re-sults:The intraoperative blood loss and nasal oozing rate of nasal cavity on the first day after the operation of the study group were lower than those in the control group(P<0.05). For patency of lacrimal passages,there was no significant difference between the groups. After the operation,the coagulation function did not change in both groups. No obvious adverse reactions were observed in both groups. Conclusion:For the patients with chronic dacryocystitis, hemocoagulase can decrease the intraoperative blood loss and postoperative nasal oozing rate of nasal cavity for dacryocystorhinostomy.